FDG-PET scanning in the diagnosis of gastrointestinal cancers

References

• Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001;2:157–64.
   Google Scholar
• Engel H, Steinert H, Buck A, Berthold T, Huch Boni RA, von Schulthess GK. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. JNucl Med 1996;37:441–6.
   Google Scholar
• Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996;26: 308–14.
   Google Scholar
• Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;20;235:1492–5.
   Google Scholar
• Monakhov NK, Neistadt EL, Shavlovskil MM, Shvartsman AL, Neifakh SA. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978;61:27–34.
   Google Scholar
• Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation and growth rates of transplanted rat tumors. Cancer Res 1970; 30:2240–4.
   PubMedGoogle Scholar
• Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991;67:1544–50.
   Google Scholar
• Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution offluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. JNucl Med 1992;33:1972–80.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Tsiaras N. Epidemiology and pathogenesis of esophageal cancer: management and its controversial results (review). Oncol Rep 2003;10:449–54.
   PubMed Web of Science ®Google Scholar
• Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64:770–6.
   PubMed Web of Science ®Google Scholar
• Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, et al. Staging of esophageal cancer with 18F- fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:417–24.
   PubMed Web of Science ®Google Scholar
• Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521–7.
   PubMedGoogle Scholar
• Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma. Clin Radiol 1998; 53:659–65.
   PubMedGoogle Scholar
• Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133–6.
   PubMed Web of Science ®Google Scholar
• Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202–10.
   Google Scholar
• Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 2000;20:713–23.
   PubMedGoogle Scholar
• Kim K, Park SJ, Kim BT, Lee KS, Shim YM. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001;71:290–4.
   Google Scholar
• Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921–8.
   PubMedGoogle Scholar
• Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300–9.
   PubMed Web of Science ®Google Scholar
• Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002;184:279–83.
   PubMedGoogle Scholar
• Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058–65.
   PubMed Web of Science ®Google Scholar
• Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8–311.
   PubMed Web of Science ®Google Scholar
• Foster JH, Lundy J. Liver métastases. Curr Probl Surg 1981;18: 157–202.
   PubMedGoogle Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;270:943–7.
   PubMed Web of Science ®Google Scholar
• Steele G, Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991;9: 1105–12.
   Google Scholar
• August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 1984;3:303–24.
   PubMed Web of Science ®Google Scholar
• Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole- body FDG-PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177–89.
   PubMed Web of Science ®Google Scholar
• Beets G, Penninckx F, Schiepers C, Filez L, Mortelmans L, Kerremans R, et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666–70.
   PubMed Web of Science ®Google Scholar
• Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517–22.
   PubMedGoogle Scholar
• Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–6.
   PubMed Web of Science ®Google Scholar
• Lai DT, Fulham M, Stephen MS, Chu KM, Solomon M, Thompson JF, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703–7.
   PubMedGoogle Scholar
• Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196–201.
   PubMed Web of Science ®Google Scholar
• Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997; 22:332–7.
   PubMedGoogle Scholar
• Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613–20.
   PubMed Web of Science ®Google Scholar
• Ruhlmann J, Schomburg A, Bender H, Oehr P, Robertz-Vaupel GM, Vaupel H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40:1195–204.
   Google Scholar
• Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227: 319–23.
   Google Scholar
• Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503–11.
   PubMedGoogle Scholar
• Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, et al. Additional value of whole-body positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17: 894–901.
   Google Scholar
• Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, et al. Clinical impact of [18]F-fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001;19: 111–8.
   PubMed Web of Science ®Google Scholar
• Simo M, Lomena F, Setoain J, Perez G, Castellucci P, Costansa JM, et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun 2002;23:975–82.
   PubMedGoogle Scholar
• Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [18F]-fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388–95.
   PubMed Web of Science ®Google Scholar
• Desai dC, Zervos EE, Arnold MW, Burak WE, Jr, Mantil J, Martin EW, Jr. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 2003;10:59–64.
   Google Scholar
• Park KC, Schwimmer J, Shepherd JE, Phelps ME, Czernin JR, Schiepers C, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001; 233: 310–9.
   PubMed Web of Science ®Google Scholar
• Oku S, Nakagawa K, Momose T, Kumakura Y, Abe A, Watanabe T, et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 2002;16:409–16.
   PubMedGoogle Scholar
• Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003;47:8–13.
   Google Scholar
• Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galanto-wicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206: 755–60.
   Google Scholar
• Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LKJ, Perrault J, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442–6.
   PubMed Web of Science ®Google Scholar
• Malesci A, Tommasini MA, Bonato C, Bocchia P, Bersani M, Zerbi A, et al. Determination of CA 19–9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987;92: 60–7.
   PubMed Web of Science ®Google Scholar
• Uehara H, Nakaizumi A, Baba M, Iishi H, Tatsuta M, Kitamura T, et al. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Am J Gastroenterol 1996;91: 1616–21.
   PubMedGoogle Scholar
• Nakamura Y, Onda M, Uchida E. Analysis of K-ras codon 12 point mutations using duodenal lavage fluid for diagnosis of pancreatic carcinoma. Pancreas 1999;18: 133–40.
   Google Scholar
• Boadas J, Mora J, Urgell E, Puig P, Roca M, Cusso X, et al. Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer. Eur J Gastroenterol Hepatol 2001;13:1153–9.
   PubMed Web of Science ®Google Scholar
• Gansauge S, Gansauge F, Negri G, Galle P, Muller J, Nussler AK, et al. The role of anti-p53-autoantibodies in pancreatic disorders. Int J Pancreatol 1996;19:171–8.
   PubMedGoogle Scholar
• Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997;38:1344–8.
   PubMed Web of Science ®Google Scholar
• Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997;38:1337–44.
   PubMed Web of Science ®Google Scholar
• Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39: 1727–35.
   PubMedGoogle Scholar
• Friess H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995;36:771–7.
   PubMed Web of Science ®Google Scholar
• Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345–52.
   PubMedGoogle Scholar
• Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995;195:339–44.
   PubMed Web of Science ®Google Scholar
• Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678–82.
   PubMedGoogle Scholar
• Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729–37.
   PubMed Web of Science ®Google Scholar
• Frohlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250–5.
   PubMed Web of Science ®Google Scholar
• Imdahl A, Nitzsche E, Krautmann F, Hogerle S, Boos S, Einert A, et al. Evaluation of positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194–9.
   PubMed Web of Science ®Google Scholar
• Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ, et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000;20:109–16.
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547–54.
   PubMed Web of Science ®Google Scholar
• Koyama K, Okamura T, Kawabe J, Nakata B, Chung KH, Ochi H, et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001;15:217–24.
   PubMed Web of Science ®Google Scholar
• Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 2001;234:675–80.
   PubMed Web of Science ®Google Scholar
• Papos M, Takacs T, Tron L, Farkas G, Ambrus E, Szakall S, Jr et al. The possible role of 18F-FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions. Clin Nucl Med 2002;27:197–201.
   PubMed Web of Science ®Google Scholar
• Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39:1030–3.
   Google Scholar
• Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784–91.
   PubMed Web of Science ®Google Scholar
• Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002;29:237–42.
   PubMed Web of Science ®Google Scholar
• Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000; 35:883–8.
   PubMed Web of Science ®Google Scholar
• Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18F-fluorodeoxy-glucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53–8.
   PubMed Web of Science ®Google Scholar
• Maisey NR, Webb A, Flux GD, Padhani A, Cunningham DC, Ott RJ, et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 2000;83:287–93.
   PubMed Web of Science ®Google Scholar
• Refa Mietten M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213–20.
   PubMedGoogle Scholar
• Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P. Demetri. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655–64.
   Google Scholar
• Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitujevic S, et al. Safety and efficacy of imatinib (ST 1571) in metastatic gastrointestinal tumors: a phase I study. Lancet 2001;358: 1421–3.
   Google Scholar
• Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Eng J Med 2002;347:472–80.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Eisenberg BL, Heinrich MC. Gastrointestinal stromal tumors. Curr Treat Options Oncol 2001;2:485–91.
   PubMedGoogle Scholar
• Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatatinib mesylate (ST1571). Eur J Cancer 2002;38 Suppl:S52–9.
   Google Scholar
• Van den Abeele aD, for the GIST Collaborative PET Study Group. F18-FDG-PET provides early evidence of biological response to ST1571 in patients with malignant gastrointestinal stromal tumors. Presented at ASCO 2001, Sarcoma abstract 1444.
   Google Scholar
• Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu M, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–9.
   PubMed Web of Science ®Google Scholar
• Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumer M, Donato di Paola E, et al. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Update of phase I study of imatinib (STI 571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2002;38: 583–7.
   Google Scholar
• Reddy MP, Reddy P, Lilien DL. F-18 FDG-PET imaging in gastrointestinal stromal tumor. Clin Nucl Med 2003;28: 677–9.
   Google Scholar
• Chander S, Lay Ergun E, Shields AF. An FDG positron emission tomographic study in a case of gastrointestinal stromal tumor. Clin Nucl Med. 2003;28:327–9.
   PubMedGoogle Scholar